Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd, an innovative biotech company, has announced the issuance of 500,000 new shares and 250,000 options to directors following shareholder approval, as part of their capital raising efforts. The company, known for pioneering next-generation diagnostics and therapeutics for cancer, including their EXO-NET technology and hTERT test for bladder cancer, is also developing clinical diagnostics for ovarian and breast cancers and exploring exosome therapeutics for solid tumors.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
